Cycle lengths for PD-(L)1 inhibitors concerned predominantly seven days (10 out of 11 models), in contrast to models of NSCLC with positive EGFR, ALK or ROS1 mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.